A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous familial hypercholesterolemia A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475o ...
A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous familial hypercholesterolemia A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475o ...
Treatment of primary dyslipidemia MedDRA version: 8;Level: PT;Classification code 10058108
Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Chole ...
A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Co-administered With Current Lipid-lowering Therapy in Subjects With Homozygous Familial Hypercholesterolemia. A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of TAK-475o ...
Hypercholesterolemia
Drug: Lapaquistat acetate and current lipid-lowering treatment;Drug: Current lipid-lowering treatment Drug: Lapaquistat acetate and current lipid-lowering treatment;Drug: Current lipid-lowering treatmen ...
Takeda
NULL
Terminated
8 Years
N/A
Both
44
Phase 3
United States;Canada;France;Israel;Poland;United Kingdom